Observation on the effect of Kunxian capsule combined with candesartan cilexetil in the treatment of chronic nephritis with hypertension
10.12206/j.issn.2097-2024.202105112
- VernacularTitle:昆仙胶囊联合坎地沙坦酯治疗慢性肾炎合并高血压疗效观察
- Author:
Linna ZHAO
1
;
Li LIU
1
;
Hongyan LI
1
;
Wencai SUN
1
;
Wen WU
1
;
Xuebin DONG
1
Author Information
1. Department of Nephrology, Hospital of the 81st Group Army of the PLA, Zhangjiakou 075000, China.
- Keywords:
chronic glomerulonephritis;
hypertension;
Kunxian capsule;
candesartan axetil;
clinical effect
- From:
Journal of Pharmaceutical Practice and Service
2022;40(5):481-484
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of Kunxian capsule combined with candesartan axetil on blood pressure, renal function, blood lipids and inflammatory factors in patients with chronic glomerulonephritis complicated with hypertension. Methods 101 patients with chronic glomerulonephritis who were admitted to our hospital from November 2017 to December 2019 were selected and randomly divided into observation group (51 cases) and control group (50 cases). The control group was treated with candesartan cilexetil on the basis of conventional treatment, and the observation group was treated with Kunxian capsule on the basis of the control group. The clinical efficacy and adverse reactions of the two groups were compared. Results The total effective rate of the observation group was significantly higher than that of the control group (P<0.05). After treatment, the blood pressure, renal function indexes (24 h Upro, BUN, Scr), blood lipid indexes (TG, TC, LDL-C), and inflammatory factors of the two groups (IL-6, hs-CRP) significantly decreased, and the observation group was significantly lower than the control group (P<0.05). After treatment, the blood lipid index HDL-C of the two groups increased significantly, and the blood lipid index HDL-C of the observation group was significantly higher than that of the control group (P<0.05). Conclusion Kunxian capsule combined with candesartan axetil can enhance the clinical efficacy, improve renal function, regulate blood lipids and reduce inflammation in patients with chronic glomerulonephritis complicated with hypertension.
